Should systemic steroids be given to infants with pertussis?

Systemic Steroids Should NOT Be Routinely Given to Infants with Pertussis

Systemic steroids are not recommended as standard treatment for pertussis in infants, as current CDC guidelines do not include corticosteroids in the treatment algorithm, and the available evidence supporting their use is limited to a single older study with methodological limitations. 1

Treatment Framework for Infant Pertussis

The established treatment approach focuses on antimicrobial therapy, not corticosteroids:

First-Line Antimicrobial Treatment

For infants <1 month (neonates):

• Azithromycin is the preferred agent (10 mg/kg/day for 5 days) 1
• Erythromycin is NOT preferred due to risk of infantile hypertrophic pyloric stenosis (IHPS)
• If erythromycin must be used, monitor closely for IHPS 1

For infants 1-5 months:

• Azithromycin remains first-line (10 mg/kg/day for 5 days) 1
• Clarithromycin is an alternative (15 mg/kg/day in 2 divided doses for 7 days) 1

For infants ≥6 months:

• Azithromycin: 10 mg/kg (max 500 mg) day 1, then 5 mg/kg/day (max 250 mg) days 2-5 1

Alternative Agents

For infants >2 months with macrolide resistance or intolerance:

• Trimethoprim-sulfamethoxazole (TMP-SMX): 8 mg/kg/day trimethoprim, 40 mg/kg/day sulfamethoxazole in 2 divided doses for 14 days 1
• Recent evidence suggests levofloxacin may be effective, though not yet in formal guidelines 2

The Limited Evidence for Steroids

The only controlled trial supporting steroid use in pertussis dates from 1973 and showed that steroids reduced coughing, whooping, and vomiting episodes, particularly in infants <1 year 3. However, this study has critical limitations:

• Published 50+ years ago with outdated methodology
• The authors themselves cautioned that steroids are "potentially dangerous drugs" and recommended limiting use to "severe cases, particularly in infants under 6 to 9 months of age where mortality is highest" 3
• No subsequent high-quality trials have validated these findings
• Not incorporated into any current CDC or major guideline recommendations 1

One review mentions steroids are "used in the management of severe neonatal pertussis" but provides no specific recommendations or evidence grade 4.

When to Consider Steroids (Severe Cases Only)

If considering steroids at all, restrict to:

• Severe pertussis with life-threatening complications
• Infants <6-9 months with critical illness
• Only as adjunctive therapy alongside appropriate antimicrobials
• After weighing risks (immunosuppression, infection risk, metabolic effects) against potential benefits

Critical caveat: The 2024 focused update on corticosteroids in critical illness addresses sepsis, ARDS, and CAP but does NOT include pertussis, suggesting insufficient evidence for routine recommendation 5.

High-Risk Infants Requiring Aggressive Management

Infants <12 months, especially <4 months, face highest mortality risk 1. For these patients:

• Hospitalize for severe disease with apnea, cyanosis, or feeding difficulties
• Provide supportive care: nasopharyngeal suction, oxygen, parenteral fluids 4
• Initiate antimicrobials immediately (azithromycin preferred)
• Monitor closely for complications (pneumonia, seizures, encephalopathy)
• Consider ICU admission for respiratory failure

Common Pitfalls to Avoid

1. Do not delay antimicrobial therapy while considering adjunctive treatments—macrolides remain the cornerstone
2. Do not use erythromycin in neonates <1 month due to IHPS risk (relative risk: infinity in one cohort) 1
3. Do not assume steroids are standard of care—they are not recommended in current guidelines
4. Do not use TMP-SMX in infants <2 months due to kernicterus risk 1
5. Do not forget postexposure prophylaxis for household contacts, especially other infants <12 months 1

Emerging Resistance Concerns

High prevalence of erythromycin-resistant Bordetella pertussis (ERBP) has been reported, particularly in China 6. In settings with known macrolide resistance:

• Consider TMP-SMX for children >2 months as initial therapy
• For infants <2 months or severe cases, consider intravenous piperacillin or cefoperazone-sulbactam 6
• Levofloxacin shows promise as an alternative with favorable safety profile 2

The evidence does not support routine corticosteroid use in infant pertussis. Focus on prompt antimicrobial therapy with azithromycin, aggressive supportive care for severe cases, and postexposure prophylaxis for contacts.